Savara (SVRA) Stock Price, News & Analysis

Company Overview

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Key Stats

• Today's Range: $2.10 to $2.29
• 50-Day Range: $1.94 to $3.40
• 52-Week Range: $1.89 to $5.11
• Volume: 2.77 million shs
• Average Volume: 1.28 million shs
• Market Capitalization: $394.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.60
• Consensus Rating: Moderate Buy

Savara Stock Analysis - MarketRank™

Savara scored higher than 51% of companies evaluated by MarketBeat, and ranked 612th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Savara has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Savara has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Savara are expected to grow in the coming year, from ($0.45) to ($0.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Savara is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Savara is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Savara has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.84% of the float of Savara has been sold short.

Short Interest Ratio / Days to Cover

Savara has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Savara has recently decreased by 1.60%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Savara does not currently pay a dividend.

Dividend Growth

Savara does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

22.84% of the float of Savara has been sold short.

Short Interest Ratio / Days to Cover

Savara has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Savara has recently decreased by 1.60%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.13

News Sentiment

Savara has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Savara this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Savara insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,179.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.13% of the stock of Savara is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SVRA Stock Analysis - Frequently Asked Questions

How have SVRA shares performed this year?

Savara's stock was trading at $3.07 at the beginning of 2025. Since then, SVRA shares have decreased by 25.7% and is now trading at $2.28.
View the best growth stocks for 2025 here.

How were Savara's earnings last quarter?

Savara Inc. (NASDAQ:SVRA) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12).

How do I buy shares of Savara?

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Savara investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Southern First Bancshares (SFST) and TotalEnergies (TTE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SVRA
• Previous Symbol: AMEX:ANX
• CIK: 1160308
• Web: www.savarapharma.com
• Phone: 512-614-1848
• Fax: 858-552-0876
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.60
• High Stock Price Target: $9.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +151.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -65.88%
• Return on Assets: -52.35%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 14.91
• Quick Ratio: 14.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 172,840,000
• Free Float: 163,970,000
• Market Cap: $384.57 million
• Optionable: Optionable
• Beta: 0.32